A. Swat

583 total citations · 1 hit paper
6 papers, 354 citations indexed

About

A. Swat is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, A. Swat has authored 6 papers receiving a total of 354 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 4 papers in Pulmonary and Respiratory Medicine and 2 papers in Cancer Research. Recurrent topics in A. Swat's work include Cancer Immunotherapy and Biomarkers (4 papers), Advanced Breast Cancer Therapies (4 papers) and Cancer Treatment and Pharmacology (3 papers). A. Swat is often cited by papers focused on Cancer Immunotherapy and Biomarkers (4 papers), Advanced Breast Cancer Therapies (4 papers) and Cancer Treatment and Pharmacology (3 papers). A. Swat collaborates with scholars based in Switzerland, United States and Germany. A. Swat's co-authors include Carlos H. Barrios, Leisha A. Emens, Volkmar Henschel, Véronique Dièras, Andreas Schneeweiß, Sherene Loi, Sylvia Adams, Eric P. Winer, Shilpen Patel and Luciana Molinero and has published in prestigious journals such as Cancer Research, Annals of Oncology and ESMO Open.

In The Last Decade

A. Swat

6 papers receiving 349 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis

2021 293 citations Leisha A. Emens, Sylvia Adams et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
A. Swat Switzerland	4	305	135	112	89	45	6	354
P. Schmid United Kingdom	3	287 0.9×	142 1.1×	113 1.0×	67 0.8×	49 1.1×	4	343
C. Zamagni Italy	7	264 0.9×	72 0.5×	121 1.1×	67 0.8×	46 1.0×	14	319
Miao Ruan China	5	204 0.7×	115 0.9×	127 1.1×	111 1.2×	126 2.8×	10	354
Michela Palleschi Italy	9	189 0.6×	133 1.0×	75 0.7×	38 0.4×	75 1.7×	46	281
M.C. Liu United States	3	418 1.4×	158 1.2×	126 1.1×	159 1.8×	79 1.8×	7	490
Dina Pietrangelo United States	3	311 1.0×	125 0.9×	71 0.6×	124 1.4×	40 0.9×	4	345
Quchang Ouyang China	10	270 0.9×	151 1.1×	69 0.6×	38 0.4×	65 1.4×	52	363
Zul Fazreen Singapore	6	282 0.9×	122 0.9×	52 0.5×	167 1.9×	72 1.6×	8	391
Lyndsey Dugan United States	6	250 0.8×	265 2.0×	230 2.1×	40 0.4×	89 2.0×	14	424
Adrien Costantini France	10	279 0.9×	146 1.1×	73 0.7×	95 1.1×	120 2.7×	25	402

Countries citing papers authored by A. Swat

Since Specialization

Citations

This map shows the geographic impact of A. Swat's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Swat with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Swat more than expected).

Fields of papers citing papers by A. Swat

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Swat. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Swat. The network helps show where A. Swat may publish in the future.

Co-authorship network of co-authors of A. Swat

This figure shows the co-authorship network connecting the top 25 collaborators of A. Swat. A scholar is included among the top collaborators of A. Swat based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Swat. A. Swat is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

6 of 6 papers shown

1.

Dent, R., Fabrice André, Anthony Gonçalvès, et al.. (2024). 180O IMpassion132 double-blind randomised phase III trial of chemotherapy (CT) ± atezolizumab (atezo) for early-relapsing unresectable locally advanced or metastatic triple-negative breast cancer (aTNBC). ESMO Open. 9. 103202–103202. 3 indexed citations

2.

Emens, Leisha A., Sylvia Adams, Carlos H. Barrios, et al.. (2021). First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis. Annals of Oncology. 32(8). 983–993. 293 indexed citations breakdown →

3.

Emens, Leisha A., Sylvia Adams, Carlos H. Barrios, et al.. (2020). LBA16 IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer. Annals of Oncology. 31. S1148–S1148. 44 indexed citations

4.

Iwata, Hitoshi, Leisha A. Emens, Sylvia Adams, et al.. (2020). 49MO IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer. Annals of Oncology. 31. S1261–S1262. 8 indexed citations

5.

Kümmel, Sherko, et al.. (2017). Abstract P4-21-42: MetaPHER phase IIIb multicenter, open-label, single-arm safety study of subcutaneous trastuzumab in combination with pertuzumab and docetaxel in patients with HER2-positive advanced breast cancer: First results. Cancer Research. 77(4_Supplement). P4–21. 3 indexed citations

6.

Kümmel, Sherko, Carina Hillenbach, A. Swat, et al.. (2016). Abstract OT3-01-13: MetaPHER: A phase IIIb multicenter, open-label, single-arm safety study of subcutaneous trastuzumab, in combination with pertuzumab and docetaxel in patients with HER2-positive advanced breast cancer. Cancer Research. 76(4_Supplement). OT3–1. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact